Sermorelin – COMPREHENSIVE RESEARCH PEPTIDE FOR GROWTH HORMONE–RELEASING HORMONE (GHRH) AND PITUITARY AXIS STUDIES

Scientific Overview of Sermorelin

Sermorelin, also known as GRF (1–29), is a synthetic peptide fragment corresponding to the first 29 amino acids of human growth hormone–releasing hormone (GHRH). This segment retains full biological activity and is widely utilized in endocrine, receptor binding, and pituitary function research.

In in-vitro and in-vivo models, Sermorelin has been investigated for its role in:

• Pituitary Somatotroph Activation – stimulation of growth hormone (GH) synthesis and secretion through GHRH receptor signaling (Thorner et al., 1981)
• GHRH Receptor Binding and Signal Transduction – analysis of cAMP-dependent pathways and downstream regulatory mechanisms (Guillemin et al., 1982)
• Endocrine Axis Modulation – examination of peptide-mediated effects on GH, IGF-1, and hypothalamic-pituitary-somatic interactions (Walker et al., 1990)

Sermorelin serves as a fundamental model peptide for exploring the physiology of growth hormone regulation, receptor pharmacodynamics, and peptide-induced endocrine signaling. It provides a reproducible platform for studying neuroendocrine and metabolic modulation within the GH axis.